Core Viewpoint - The announcement of a licensing agreement between Lai Kai Pharmaceutical and Qilu Pharmaceutical for the commercialization of the breast cancer candidate drug LAE002 (Afuresertib) in China has positively impacted Lai Kai's stock price, which rose by 4.24% to HKD 11.8 [1] Group 1: Licensing Agreement Details - Lai Kai Pharmaceutical has entered into an exclusive licensing agreement with Qilu Pharmaceutical for LAE002, aimed at accelerating its commercialization in China [1] - The agreement stipulates that Lai Kai is entitled to receive a non-refundable upfront payment of up to RMB 530 million and milestone payments related to clinical development until the first indication receives new drug application approval in China [1] - Additionally, Lai Kai is eligible for a total of up to RMB 2.045 billion in upfront and milestone payments, along with a tiered sales revenue share ranging from over ten percentage points to over twenty percentage points on future net sales in China [1] Group 2: Clinical Trial Progress - The Phase III clinical trial (AFFIRM-205) for LAE002 targeting HR+/HER2- breast cancer is currently progressing as planned [1]
来凯医药-B高开逾4% 与齐鲁制药就LAE002订立独家许可协议